HilleVax, Inc. (HLVX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HilleVax, Inc. (HLVX) with AI Score 47/100 (Weak). HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026HilleVax, Inc. (HLVX) Healthcare & Pipeline Overview
HilleVax, Inc. is a clinical-stage biopharmaceutical company specializing in vaccine development, with a primary focus on HIL-214, a virus-like particle vaccine targeting norovirus. The company operates within the competitive biotechnology sector, aiming to address the unmet need for norovirus prevention.
Investment Thesis
HilleVax presents a focused investment opportunity within the biotechnology sector, centered on its lead candidate, HIL-214, for norovirus prevention. The potential market for a norovirus vaccine is substantial, given the high incidence and morbidity associated with the virus. Successful clinical trials and regulatory approval of HIL-214 could drive significant revenue growth for HilleVax. Key value drivers include the progress of HIL-214 through clinical development, strategic partnerships, and potential expansion of the vaccine pipeline. The company's market capitalization is $0.10 billion, with a P/E ratio of -1.47 and a beta of 0.77. However, the company faces risks associated with clinical trial outcomes, regulatory hurdles, and competition from other vaccine developers.
Based on FMP financials and quantitative analysis
Key Highlights
- HilleVax is a clinical-stage biopharmaceutical company focused on vaccine development.
- The company's lead product candidate, HIL-214, targets norovirus infection.
- HIL-214 is a virus-like particle (VLP)-based vaccine.
- The company is headquartered in Boston, Massachusetts.
- HilleVax has a market capitalization of $0.10 billion.
Competitors & Peers
Strengths
- Proprietary VLP technology platform.
- Focus on a significant unmet medical need (norovirus prevention).
- Experienced management team.
- Strong intellectual property position.
Weaknesses
- Clinical-stage company with no approved products.
- Reliance on the success of HIL-214.
- Limited financial resources.
- Small number of employees.
Catalysts
- Upcoming: Announcement of Phase 2 clinical trial results for HIL-214 (expected in Q4 2026).
- Upcoming: Initiation of Phase 3 clinical trials for HIL-214 (expected in H1 2027).
- Ongoing: Progress in discussions with regulatory agencies regarding the approval pathway for HIL-214.
- Ongoing: Potential partnerships with pharmaceutical companies for the commercialization of HIL-214.
Risks
- Potential: Clinical trial failures or delays for HIL-214.
- Potential: Regulatory hurdles in obtaining approval for HIL-214.
- Potential: Competition from other vaccine developers.
- Ongoing: Dependence on the success of HIL-214.
- Ongoing: Limited financial resources.
Growth Opportunities
- Expansion of HIL-214 into new markets: HilleVax has the opportunity to expand the reach of HIL-214 beyond its initial target markets, such as the United States and Europe. This could involve seeking regulatory approval in additional countries, particularly in developing regions where norovirus infection is prevalent. The global market for vaccines is projected to reach $100 billion by 2025, providing a substantial opportunity for HilleVax to increase its revenue and market share.
- Development of new vaccine candidates: HilleVax can leverage its VLP technology platform to develop additional vaccine candidates against other infectious diseases. This could involve targeting diseases with significant unmet medical needs or developing combination vaccines that protect against multiple infections. The company's expertise in VLP technology provides a competitive advantage in the development of novel vaccines.
- Strategic partnerships and collaborations: HilleVax can pursue strategic partnerships and collaborations with other pharmaceutical companies, research institutions, or government agencies to accelerate the development and commercialization of its vaccine candidates. This could involve licensing agreements, joint ventures, or research collaborations. Strategic partnerships can provide access to additional resources, expertise, and funding.
- Advancements in vaccine technology: HilleVax can invest in research and development to improve its VLP technology platform and develop more effective and efficient vaccines. This could involve exploring new adjuvants, delivery systems, or manufacturing processes. Advancements in vaccine technology can enhance the immunogenicity and safety of vaccines, leading to improved clinical outcomes.
- Addressing emerging infectious diseases: HilleVax can adapt its VLP technology platform to develop vaccines against emerging infectious diseases, such as novel coronaviruses or influenza strains. This would require rapid response capabilities and the ability to quickly develop and test new vaccine candidates. Addressing emerging infectious diseases can provide a significant opportunity for HilleVax to contribute to global public health and generate revenue.
Opportunities
- Expansion into new markets and indications.
- Strategic partnerships and collaborations.
- Advancements in vaccine technology.
- Addressing emerging infectious diseases.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Changes in the healthcare landscape.
Competitive Advantages
- Proprietary VLP technology platform for vaccine development.
- Intellectual property protection for HIL-214 and other vaccine candidates.
- Expertise in vaccine development and clinical trials.
- Established relationships with key opinion leaders and regulatory agencies.
About HLVX
HilleVax, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative vaccines to prevent infectious diseases. The company's lead product candidate, HIL-214, is a virus-like particle (VLP)-based vaccine designed to prevent moderate-to-severe acute gastroenteritis caused by norovirus infection. Norovirus is a highly contagious virus that causes significant morbidity and mortality worldwide, particularly among young children and the elderly. HilleVax aims to address this substantial unmet medical need with a safe and effective vaccine. The company's focus on norovirus reflects the significant public health burden and commercial opportunity associated with this infection. HIL-214 is currently undergoing clinical trials to assess its safety and efficacy. HilleVax's strategy involves leveraging its VLP technology platform to develop additional vaccines against other infectious diseases in the future. The company is headquartered in Boston, Massachusetts, and operates with a team of experienced vaccine development professionals. HilleVax is committed to advancing its pipeline of vaccine candidates and improving global public health.
What They Do
- Develop virus-like particle (VLP)-based vaccines.
- Focus on preventing moderate-to-severe acute gastroenteritis caused by norovirus infection.
- Conduct clinical trials to assess the safety and efficacy of HIL-214.
- Seek regulatory approval for HIL-214 from health authorities.
- Commercialize vaccines to prevent infectious diseases.
- Leverage VLP technology to develop additional vaccines.
Business Model
- Develop and patent novel vaccine candidates.
- Conduct clinical trials to demonstrate safety and efficacy.
- Obtain regulatory approval from health authorities.
- Manufacture and commercialize vaccines through direct sales or partnerships.
Industry Context
HilleVax operates within the biotechnology industry, which is characterized by high growth potential and significant investment in research and development. The vaccine market is a key segment within the biotechnology industry, driven by increasing awareness of infectious diseases and the importance of preventive healthcare. The competitive landscape includes established pharmaceutical companies and emerging biotechnology firms focused on vaccine development. HilleVax aims to differentiate itself through its VLP technology platform and its focus on norovirus prevention, a significant unmet medical need.
Key Customers
- Healthcare providers who administer vaccines to patients.
- Government agencies that purchase vaccines for public health programs.
- Individuals seeking to prevent norovirus infection.
- Pharmacies and distributors.
Financials
Chart & Info
HilleVax, Inc. (HLVX) stock price: Price data unavailable
Latest News
-
Kosmos Energy Posts Downbeat Q2 Results, Joins HilleVax And Other Big Stocks Moving Lower In Monday's Pre-Market Session
benzinga · Aug 4, 2025
-
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
benzinga · Oct 3, 2022
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Jun 14, 2022
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · May 25, 2022
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HLVX.
Price Targets
Wall Street price target analysis for HLVX.
MoonshotScore
What does this score mean?
The MoonshotScore rates HLVX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Kosmos Energy Posts Downbeat Q2 Results, Joins HilleVax And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Stocks That Hit 52-Week Lows On Tuesday
Stocks That Hit 52-Week Lows On Wednesday
Leadership: Robert M. Hershberg
CEO
Robert M. Hershberg is the CEO of HilleVax, Inc. He brings extensive experience in the biopharmaceutical industry, with a background in medicine and drug development. Prior to joining HilleVax, he held leadership positions at various biotechnology companies, where he oversaw the development and commercialization of innovative therapies. His expertise spans clinical development, regulatory affairs, and business strategy. He is responsible for managing 14 employees at HilleVax.
Track Record: Under Robert Hershberg's leadership, HilleVax has focused on advancing HIL-214 through clinical trials and building a strong intellectual property position. He has overseen the company's strategic direction and efforts to secure funding for its vaccine development programs. Key milestones include initiating clinical trials for HIL-214 and establishing partnerships to support the company's growth.
HLVX Healthcare Stock FAQ
What does HilleVax, Inc. do?
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines to prevent infectious diseases. Its primary focus is on HIL-214, a virus-like particle (VLP)-based vaccine candidate designed to prevent moderate-to-severe acute gastroenteritis caused by norovirus infection. The company aims to address the significant unmet medical need for a norovirus vaccine, leveraging its VLP technology platform and expertise in vaccine development to improve global public health.
What do analysts say about HLVX stock?
Analyst coverage of HLVX is still emerging, given its status as a clinical-stage biopharmaceutical company. Key valuation metrics to consider include the potential market size for a norovirus vaccine, the probability of success for HIL-214 in clinical trials, and the company's long-term growth prospects. Analyst consensus will likely depend on the progress of HIL-214 through clinical development and any strategic partnerships or collaborations that the company establishes. The company's market capitalization is $0.10 billion, with a P/E ratio of -1.47 and a beta of 0.77.
What are the main risks for HLVX?
The main risks for HilleVax include the inherent uncertainties associated with clinical-stage drug development. Clinical trial failures or delays for HIL-214 could significantly impact the company's prospects. Regulatory hurdles in obtaining approval for HIL-214 also pose a risk. Additionally, the company faces competition from established pharmaceutical companies and other vaccine developers. HilleVax's limited financial resources and dependence on the success of HIL-214 are also key risk factors to consider.
What are the key factors to evaluate for HLVX?
HilleVax, Inc. (HLVX) currently holds an AI score of 47/100, indicating low score. Key strength: Proprietary VLP technology platform.. Primary risk to monitor: Potential: Clinical trial failures or delays for HIL-214.. This is not financial advice.
How frequently does HLVX data refresh on this page?
HLVX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HLVX's recent stock price performance?
Recent price movement in HilleVax, Inc. (HLVX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary VLP technology platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HLVX overvalued or undervalued right now?
Determining whether HilleVax, Inc. (HLVX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HLVX?
Before investing in HilleVax, Inc. (HLVX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.